The NHL has handed down a 20-game suspension to Pittsburgh Penguins defenseman Caleb Jones for violating the league's Performance Enhancing Substances Program. Jones, currently on injured reserve, tested positive for a prohibited substance. The suspension marks a significant setback for the defenseman, who signed a two-year deal with the Penguins last summer.

Jones claims the positive test resulted from a contaminated substance during exosome therapy. He expressed remorse for disappointing his teammates, the Penguins organization, and the fans. General Manager Kyle Dubas stated the team supports Jones through the suspension. Jones' brother, Seth Jones, plays defense for the Florida Panthers, and has had a strong NHL career.

This suspension comes as a blow to the Penguins, who are looking to solidify their defensive core. Jones had played seven games, recording one point before being sidelined with a foot injury. The team will now need to adjust their roster and strategy. The NHL's stance on PEDs remains firm, especially with player safety being a priority.

With Jones sidelined, the Penguins will need other players to step up to fill the void. The team's depth will be tested during the suspension period. The situation also raises questions about the oversight of medical treatments players receive from outside providers and how the NHL and NHLPA will address the issue.